Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,127Revenue (TTM) $M1.3Net Margin (%)-19,049.6Altman Z-Score0.0
Enterprise Value $M1,019EPS (TTM) $-5.4Operating Margin %-18,995.8Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.3Pre-tax Margin (%)-19,049.6Higher ROA y-yN
Price/Book9.410-y EBITDA Growth Rate %2.4Quick Ratio2.9Cash flow > EarningsY
Price/Sales8215-y EBITDA Growth Rate %36.1Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-161.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.8ROIC % (ttm)-908.2Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 24.6246%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 24.629%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 24.62-22%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 24.62-3%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 24.62-17%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 24.62-36%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 24.62-15%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 24.62-8%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 24.62281%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 24.62398%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 24.62213%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 24.62154%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2848.83view
Barry RichardDirector 2016-03-14Buy75,000$15.6654.73view
Price Ben GilDirector 2016-03-14Buy4,500$16.745.09view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82104.99view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82104.99view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9573.69view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5692.91view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-34.58view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-30.71view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-25.86view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate... Jul 26 2016
Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss Jul 20 2016
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus Jul 20 2016
Morning Movers: Morgan Stanley Jumps on Earnings; Valeant Pharmaceuticals Climbs on Drug Approval Jul 20 2016
Sarepta Therapeutics reports 2Q loss Jul 19 2016
Sarepta Therapeutics reports 2Q loss Jul 19 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 19 2016
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate... Jul 19 2016
Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD Jul 14 2016
Is There Hope for Sarepta? Jul 14 2016
Sarepta Therapeutics stock slumps 3.5% after other DMD drug is denied accelerated approval Jul 14 2016
Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay Jul 14 2016
Coverage Initiated on Select Biotech Equities Jul 12 2016
[$$] Where's the Drug, FDA? Jul 05 2016
Sarepta Stock Price Lifted by 'No Bad News Is Good News' Argument Jul 05 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)